| ID Source | ID |
|---|---|
| PubMed CID | 23675317 |
| CHEMBL ID | 2364720 |
| CHEBI ID | 31987 |
| SCHEMBL ID | 34264 |
| MeSH ID | M0263002 |
| Synonym |
|---|
| phenethicillin potassium |
| PRESTWICK_142 |
| 132-93-4 |
| NCGC00017019-01 |
| cas-132-93-4 |
| syncillin (tn) |
| pheneticillin potassium |
| D01178 |
| synthepen (tn) |
| phenethicillin potassium (jp17) |
| phenoxyaethylpenicillin k-salz [german] |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxypropyl)amino)-, monopotassium salt, (2s-(2alpha,5alpha,6beta))- |
| potassium methylphenoxymethylpenicillin |
| 6-(a-phenoxypropionamido)penicillanic acid potassium salt |
| synerpenin |
| ro-cillin |
| astracillin |
| 3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxypropyl)amino)-4-thia-1-azabicyclo(3.2.0)-heptane-2-carboxylic acid potassium salt |
| potassium 6-(alpha-phenoxypropionamido)penicillanate |
| brocsil |
| hsdb 3167 |
| synthepen tabl |
| penicillin-152 |
| potassium (1-phenoxyethyl)penicillin |
| dramcillin-s |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxypropyl)amino)-, (2s-(2alpha,5alpha,6beta))-, monopotassium salt |
| pen 200 |
| einecs 205-084-4 |
| a-phenoxyethylpenicillinic acid potassium salt |
| peniplus |
| penemve |
| synapen |
| alpha-phenoxyethylpenicillin potassium salt |
| priospen |
| synthecillin |
| penicillin mv |
| alticina |
| k phenethicillin |
| pensig |
| alpha-oracillin |
| potassium (alpha-phenoxyethyl)penicillin |
| chemipen |
| darcil |
| triospen |
| bendralan |
| optipen |
| potassium phenethicillin |
| oralopen |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxypropionamido)-, monopotassium salt |
| synthecilline |
| penova |
| chemipen-c |
| maxipen |
| syncillin |
| alfacillin |
| monopotassium (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxypropionamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate |
| penicillin-152 potassium |
| feneticilline |
| brl 152 |
| semopen |
| phenethicillin potassium [jan] |
| pheno-m-penicillin |
| broxil |
| SPECTRUM1500643 |
| CHEBI:31987 , |
| potassium 6beta-(2-phenoxypropanamido)-2,2-dimethylpenam-3alpha-carboxylate |
| HMS2092E16 |
| HMS500L16 |
| HMS1570A08 |
| HMS2097A08 |
| tox21_110739 |
| dtxsid5045546 , |
| dtxcid3025546 |
| phenoxyaethylpenicillin k-salz |
| CCG-39275 |
| unii-70978wuk7c |
| 70978wuk7c , |
| phenethicillin potassium [usp:jan] |
| phenethicillin potassium [mi] |
| phenethicillin potassium [hsdb] |
| monopotassium (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxypropionamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| pheneticillin potassium [mart.] |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxypropyl)amino)-, 92s-(2.alpha.,5.alpha.,6.beta.))-, monopotassium salt |
| pheneticillin potassium [who-dd] |
| phenethicillin k salt |
| dramcillin s |
| CHEMBL2364720 |
| SCHEMBL34264 |
| phenethicillin-kalium |
| HMS3714A08 |
| potassium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxypropanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| Q27114742 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| organic potassium salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 10.1235 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.65) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||